25 results on '"Valdesoiro-Navarrete L"'
Search Results
2. Position document: IgE-mediated cow's milk allergy
- Author
-
Martorell-Aragonés, A., Echeverría-Zudaire, L., Alonso-Lebrero, E., Boné-Calvo, J., Martín-Muñoz, M.F., Nevot-Falcó, S., Piquer-Gibert, M., and Valdesoiro-Navarrete, L.
- Published
- 2015
- Full Text
- View/download PDF
3. Guidelines for the follow up of patients with bronchopulmonary dysplasia
- Author
-
Pérez Tarazona, S., Rueda Esteban, S., Alfonso Diego, J., Barrio Gómez de Agüero, M.I., Callejón Callejón, A., Cortell Aznar, I., de la Serna Blázquez, O., Domingo Miró, X., García García, M.L., García Hernández, G., Luna Paredes, C., Mesa Medina, O., Moreno Galdó, A., Moreno Requena, L., Pérez Pérez, G., Salcedo Posadas, A., Sánchez Solís de Querol, M., Torrent Vernetta, A., Valdesoiro Navarrete, L., and Vilella Sabaté, M.
- Published
- 2016
- Full Text
- View/download PDF
4. Protocolo de seguimiento de los pacientes con displasia broncopulmonar
- Author
-
Pérez Tarazona, S., Rueda Esteban, S., Alfonso Diego, J., Barrio Gómez de Agüero, M.I., Callejón Callejón, A., Cortell Aznar, I., de la Serna Blázquez, O., Domingo Miró, X., García García, M.L., García Hernández, G., Luna Paredes, C., Mesa Medina, O., Moreno Galdó, A., Moreno Requena, L., Pérez Pérez, G., Salcedo Posadas, A., Sánchez Solís de Querol, M., Torrent Vernetta, A., Valdesoiro Navarrete, L., and Vilella Sabaté, M.
- Published
- 2016
- Full Text
- View/download PDF
5. 197 Longitudinal assessment of Pseudomonas aeruginosa in children with cystic fibrosis. Differences with healthy infants
- Author
-
Valdesoiro-Navarrete, L., primary, Espasa, M., additional, Rodrigo, C., additional, Domingo, C., additional, Asensio, Ò., additional, López, N., additional, and Bosque-García, M., additional
- Published
- 2011
- Full Text
- View/download PDF
6. Microbiology of the respiratory tract in cystic fibrosis patients diagnosed by neonatal screening: differences with healthy patients
- Author
-
Valdesoiro-Navarrete, L., primary, Bosque, M., additional, Rodrigo, C., additional, López, N., additional, Valiente, A., additional, Asensio, O., additional, Larramona, H., additional, and Domingo, Ch., additional
- Published
- 2010
- Full Text
- View/download PDF
7. Bacteriemia oculta por Kingella kingae
- Author
-
Pineda Solas, V., primary, Valdesoiro Navarrete, L., additional, Fontanals Aymerich, D., additional, Llimiñana Ordas, C., additional, Antón López, J., additional, and Cabezas Maspoch, M.R., additional
- Published
- 2002
- Full Text
- View/download PDF
8. Abscesos esplénicos y enfermedad por arañazo de gato
- Author
-
Valdesoiro Navarrete, L., Pineda Solas, V., Martín Martín, C., Sanfeliu Sala, I., Sánchez Oespina, M., and Cabezas Maspoch, R.M.<ce:sup loc='post">a</ce:sup>
- Published
- 2001
- Full Text
- View/download PDF
9. Response letter to the article published in Anales de Pediatría: «School children with chronic diseases; what are teachers worried about?» Let's not forget asthma!
- Author
-
Moreno-Galarraga L and Valdesoiro Navarrete L
- Subjects
- Humans, Child, Chronic Disease, School Teachers, Asthma diagnosis
- Published
- 2024
- Full Text
- View/download PDF
10. Impact of treatment adherence and inhalation technique on asthma outcomes of pediatric patients: a longitudinal study.
- Author
-
Lizano-Barrantes C, Garin O, Mayoral K, Dima AL, Pont A, Caballero-Rabasco MA, Praena-Crespo M, Valdesoiro-Navarrete L, Guerra MT, Bercedo-Sanz A, and Ferrer M
- Abstract
Introduction: We aimed to evaluate the longitudinal relationships, both at between- and within-person levels, that adherence to inhaled corticosteroid-based maintenance treatment and inhalation technique present with symptom control, exacerbations, and health-related quality of life (HRQoL) in children and adolescents with asthma. Methods: Participants (6-14 years old) from the ARCA (Asthma Research in Children and Adolescents) cohort-a prospective, multicenter, observational study (NCT04480242)-were followed for a period from 6 months to 5 years via computer-assisted telephone interviews and a smartphone application. The Medication Intake Survey-Asthma (MIS-A) was administered to assess the implementation stage of adherence, and the Inhalation Technique Questionnaire (InTeQ) was used to assess the five key steps when using an inhaler. Symptom control was measured with the Asthma Control Questionnaire (ACQ), and HRQL was measured with the EQ-5D and the Patient-Reported Outcomes Measurement Information System-Pediatric Asthma Impact Scale (PROMIS-PAIS). Multilevel longitudinal mixed models were constructed separately with symptom control, exacerbation occurrence, EQ-5D, and PROMIS-PAIS as the dependent variables. Results: Of the 360 participants enrolled, 303 (1,203 interviews) were included in the symptom control and exacerbation analyses, 265 (732) in the EQ-5D, and 215 (617) in the PROMIS-PAIS. Around 60% of participants were male subjects, and most of them underwent maintenance treatment with inhaled corticosteroids plus long-acting β-agonists in a fixed dose (73.3%). Within-person variability was 83.6% for asthma control, 98.6% for exacerbations, 36.4% for EQ-5D, and 49.1% for PROMIS-PAIS. At the within-person level, patients with higher adherence had better symptom control ( p = 0.002) and HRQoL over time ( p = 0.016). Patients with a better inhalation technique reported worse HRQoL simultaneously ( p = 0.012), but they showed better HRQoL in future assessments ( p = 0.012). The frequency of reliever use was associated with symptom control ( p < 0.001), exacerbation occurrence ( p < 0.001), and HRQoL ( p = 0.042); and boys were more likely to present better symptom control and HRQoL than girls. Conclusion: Our results confirm longitudinal associations at the within-person level of the two indicators of quality use of inhalers: for adherence to maintenance treatment with symptom control and HRQoL, and for the inhalation technique with HRQoL. Although treatment adherence was shown to be excellent, a third of the participants reported a suboptimal inhalation technique, highlighting the need for actions for improving asthma management of the pediatric population., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Lizano-Barrantes, Garin, Mayoral, Dima, Pont, Caballero-Rabasco, Praena-Crespo, Valdesoiro-Navarrete, Guerra, Bercedo-Sanz and Ferrer.)
- Published
- 2024
- Full Text
- View/download PDF
11. Inhaled medications and inhalation chambers for childhood asthma. Spanish network of working groups on asthma in pediatrics (REGAP).
- Author
-
Juliá Benito JC, Moreno-Galarraga L, Bragado Alcaraz E, Asensi Monzó MT, Ortega Casanueva C, Moral L, Rodríguez Fernández-Oliva CR, Sanz Ortega J, and Valdesoiro Navarrete L
- Subjects
- Humans, Child, Administration, Inhalation, Nebulizers and Vaporizers, Chronic Disease, Educational Status, Asthma drug therapy
- Abstract
Asthma, the most prevalent chronic disease in pediatric age, continues to pose challenges in its management and treatment. National and international guidelines emphasize the importance of therapeutic education (TE) to achieve disease control. TE involves imparting knowledge and skills to the patient and their family, enhancing medication adherence, rectifying errors in inhalation technique, and tailoring treatment based on individual patient characteristics. It is essential for TE to be progressive, gradual, and personalized, spanning all levels of care. Training healthcare professionals in TE is crucial, particularly for pediatricians, who must also be aware of the extensive variability of available meds and inhalers and their respective age-specific indications. Addressing this need, the REGAP Group extensively reviewed inhalers currently available in Spain for pediatric asthma treatment. The review encompassed different inhalation systems and inhaled drugs used for pediatric asthma treatment. This review will be updated annually, providing information on medications, devices, inhalation chambers, indications, and financiation. The REGAP Group hopes that these tables will be a valuable help for pediatricians in their daily clinical practice and serve as an effective TE tool., (Copyright © 2023 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.
- Author
-
Mayoral K, Lizano-Barrantes C, Zamora V, Pont A, Miret C, Barrufet C, Caballero-Rabasco MA, Praena-Crespo M, Bercedo A, Valdesoiro-Navarrete L, Guerra MT, Pardo Y, Martínez Zapata MJ, Garin O, and Ferrer M
- Subjects
- Adolescent, Humans, Child, Quality of Life, Adrenal Cortex Hormones therapeutic use, Asthma diagnosis, Asthma drug therapy, Rhinitis, Allergic diagnosis, Rhinitis, Allergic drug therapy
- Abstract
Background: We aim to assess the impact of montelukast on paediatric patients with asthma/allergic rhinitis, measured using patient-reported outcome measures, compared with other treatments or placebo., Methods: Protocol registration CRD42020216098 (www.crd.york.ac.uk/PROSPERO). MEDLINE and Embase databases were used to conduct the search. Two authors independently selected studies and extracted data, and a third reviewer resolved discrepancies. Meta-analyses were constructed to estimate the standardised mean difference (SMD) using a random-effects model., Results: Out of 3937 articles identified, 49 studies met the inclusion criteria, mostly randomised clinical trials (sample sizes: 21-689 patients). The SMD of change pooled estimators for the global, mental and physical domains of health-related quality of life were not statistically significant. For daytime and night-time symptoms scores, the SMD (95% CI) was in favour of inhaled corticosteroids (-0.12, -0.20- -0.05 and -0.23, -0.41- -0.06, respectively). The pooled estimator for global asthma symptoms was better for montelukast when compared with placebo (0.90, 0.44-1.36)., Conclusions: The synthesis of the available evidence suggests that, in children and adolescents, montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms, especially at night-time. These findings of our systematic review concur with current guidelines for asthma treatment., Competing Interests: Conflict of interest: All authors have nothing to disclose., (Copyright ©The authors 2023.)
- Published
- 2023
- Full Text
- View/download PDF
13. Prevalence and Impact of Asthma and Allergy on Daily Life, Health Outcomes and Use of Healthcare Services in Children: A Population-Based Study.
- Author
-
González-de Paz L, Valdesoiro-Navarrete L, Roma J, Blat-Guimerà E, Benavent-Areu J, Bartra J, and Sisó-Almirall A
- Subjects
- Child, Humans, Adolescent, Prevalence, Delivery of Health Care, Outcome Assessment, Health Care, Quality of Life, Asthma epidemiology, Asthma therapy, Asthma etiology
- Abstract
Introduction: Studies on the prevalence of asthma and allergies often lack representation of the pediatric population, and their impact has not been examined using children without these diseases as a reference group. This study aimed to determine the prevalence of asthma and allergies in children under 14 years old in Spain and their impact on health-related quality of life, activities, healthcare utilization, and environmental and household exposure risk factors., Methods: Data came from a Spanish population-based representative survey of children aged <14 years (N=6297). A sample of controls (1:4) from the same survey was matched using propensity score matching. Logistic regression models and population-attributable fractions were calculated to determine the impact of asthma and allergy., Results: The population prevalence of asthma was 5.7% (95% CI: 5.0%, 6.4%), and of allergy was 11.4% (95% CI: 10.5%, 12.4. In children with lower percentiles of health-related quality of life (≤20th), 32.3% (95% CI, 13.6%, 47.0%) was attributed to asthma and 27.7% (95% CI: 13.0%, 40.0%) to allergy. Forty-four percent of restrictions in usual activity were attributed to asthma (OR: 2.0, p-value: <0.001), and 47.9% to allergy (OR: 2.1, p-value: <0.001). 62.3% of all hospital admissions were attributed to asthma (OR: 2.8, p-value: <0.001), and 36.8% (OR: 2.5, p-value: <0.001) of all specialist consults to allergy., Conclusions: The high prevalence of atopic disease and its impact on daily life and healthcare utilization call for an integrated healthcare system focused on children and caregivers' needs with continuity of care across education and healthcare settings., (Copyright © 2023 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Inhaler Technique Questionnaire (InTeQ) in pediatric patients with asthma.
- Author
-
Lizano-Barrantes C, Garin O, Dima AL, Mayoral K, Pont A, Ortiz EM, Caballero-Rabasco MA, Praena-Crespo M, Valdesoiro-Navarrete L, Guerra MT, Bercedo-Sanz A, Hernández G, Maroni C, de Mir I, Carrasco MÁ, Ortega M, Servan A, Castillo JA, Tato E, and Ferrer M
- Subjects
- Humans, Child, Nebulizers and Vaporizers, Surveys and Questionnaires, Administration, Inhalation, Asthma drug therapy
- Published
- 2023
- Full Text
- View/download PDF
15. Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain.
- Author
-
Nieto-Cid M, Garriga-Baraut T, Plaza-Martín AM, Tortajada-Girbés M, Torres-Borrego J, Lozano-Blasco J, Moreno-Galarraga L, Del Mar Folqué-Giménez M, Bosque-García M, Gaboli M, López-Neyra A, Rivas-Juesas C, Caballero-Rabasco MA, Freixa-Benavente A, Valdesoiro-Navarrete L, de Mir-Messa I, Ballester-Asensio E, Penín-Antón M, Romero-García R, Navarro-Morón J, Valenzuela-Soria A, Sánchez-Mateos M, Batlles-Garrido J, Sanz-Santiago V, de Atauri ÁG, Andrés-Martín A, Campos-Alonso E, Gómez-Pastrana D, Vázquez-Rodríguez E, Martínez-Pardo L, Del Río-Camacho G, Mazón-Ramos Á, and Nieto-García A
- Subjects
- Humans, Child, Omalizumab therapeutic use, Cost-Benefit Analysis, Spain, Retrospective Studies, Treatment Outcome, Quality of Life, Anti-Asthmatic Agents therapeutic use, Asthma therapy
- Abstract
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost-effective., Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real-life in Spain) study was used to calculate the incremental cost-effectiveness ratio (ICER) for the avoidance of moderate-to-severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c-ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab., Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c-ACT, at years 1 and 6, respectively., Conclusion: The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment., (© 2023 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
16. Consensus document on the primary prevention of cow's milk protein allergy in infants aged less than 7 days.
- Author
-
Díaz Martín JJ, Blesa Baviera L, Campoy Folgoso C, Espín Jaime B, Leis Trabazo MR, Mesa Del Castillo M, Martín Masot R, Martinez-Cañavate Burgos A, Martorell Aragones A, Molina Arias M, Roman Riechmann E, Saenz de Pipaón M, and Valdesoiro Navarrete L
- Subjects
- Animals, Cattle, Female, Humans, Consensus, Primary Prevention, Food Hypersensitivity, Milk Hypersensitivity etiology, Milk Hypersensitivity prevention & control
- Abstract
Introduction: Cow's milk protein allergy (CMPA) is the most frequent food allergy in the first year of life. There is no clear consensus regarding its prevention. A recommendation to avoid CMP in the first week of life as a preventive measure in all infants, regardless of their atopic risk, has recently been published. The purpose of this document is to issue a recommendation on the use of extensively hydrolyzed CMP formulas in the first week of life for the primary prevention of CMPA., Methods: A group of experts was formed with members proposed by the Spanish Association of Pediatrics (AEP), the Spanish Society of Clinical Immunology and Allergology and Pediatric Asthma (SEICAAP), the Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition (SEGHNP) and the Spanish Society of Neonatology (SENEO). The group conducted a critical review of the evidence on the subject published in the last 10 years., Results: The search yielded 72 studies, of which 66 were rejected for not meeting the inclusion criteria. The final review included 6 documents: 3 clinical trials and 3 systematic reviews, 2 of them with meta-analysis. There was no evidence of a statistically significant reduction in the incidence of CMPA in the infants who received hypoallergenic formulae or exclusive breastfeeding., Conclusion: Based on the current evidence, it is not possible to draw clear conclusions about the effect of avoiding CMP in the first week of life for prevention of CMPA. Although there are data that suggest a certain beneficial effect of avoiding CMPA in atopic risk infants, these results are not conclusive enough to extend the recommendation to the general population., (Copyright © 2022 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
17. Long-term outcome of omalizumab-assisted desensitisation to cow's milk and eggs in patients refractory to conventional oral immunotherapy: real-life study.
- Author
-
Ayats-Vidal R, Riera-Rubió S, Valdesoiro-Navarrete L, García-González M, Larramona-Carrera H, Cruz OA, and Bosque-García M
- Subjects
- Administration, Oral, Animals, Cattle, Chickens, Child, Desensitization, Immunologic adverse effects, Female, Humans, Immunologic Factors, Milk adverse effects, Omalizumab therapeutic use, Retrospective Studies, Anaphylaxis etiology, Milk Hypersensitivity therapy
- Abstract
Background: Oral immunotherapy (OIT) is a promising approach to cow's milk and egg allergies, but reactions are frequent and some patients cannot be desensitized., Objective: To evaluate long-term OIT outcomes with omalizumab (OMZ) in paediatric patients with severe egg and/or milk allergies., Methods: This retrospective real-life study analysed findings in children with Immunoglobulin E-mediated allergy to cow's milk and/or hen eggs refractory to conventional OIT, who underwent OIT with OMZ in our department between 1 January 2010 and 31 December 2015., Results: In all, 41 patients were included (median age: 7 years; interquartile range [IQR]: 5.5-9.5); 26/41 (63.4%) underwent OIT for milk, 8/41 (19.5%) for egg and 7/41 (17.1%) for both. The median time between initiation of OMZ and OIT was 27 weeks (IQR: 22-33). Forty (97.56%) patients reached the maintenance phase (200 mL of cow's milk and 30 mL of raw egg or 1 cooked egg) in a median time of 27 weeks (IQR: 18-37). The median total time with OMZ was 117 weeks (IQR: 88-144). During the OMZ period, 2.44% (1/41) of patients presented anaphylaxis. After discontinuation of OMZ, 29.3% (12/41) presented anaphylaxis, 50% of them had a poor adherence to daily ingestion. One patient (2.44%) was diagnosed with eosinophilic esophagitis after 2 years of discontinuation of OMZ. Currently, after a median time of 9 years (IQR: 7-10) since the initiation of OMZ, 75.6% (31/41) are desensitized (27/31 without OMZ)., Conclusions: Omalizumab allows desensitisation of children with severe allergies to cow's milk and/or egg without developing severe reactions while receiving this treatment. However, discontinuation of OMZ leads to severe allergic reactions, and hence must be monitored carefully.
- Published
- 2022
- Full Text
- View/download PDF
18. Measurement properties of the EQ-5D-Y administered through a smartphone app in children with asthma: a longitudinal questionnaire study.
- Author
-
Mayoral K, Garin O, Lizano-Barrantes C, Pont A, Caballero-Rabasco AM, Praena-Crespo M, Valdesoiro-Navarrete L, Guerra MT, Castillo JA, Mir I, Tato E, Alonso J, Serra-Sutton V, Pardo Y, and Ferrer M
- Subjects
- Child, Humans, Prospective Studies, Quality of Life psychology, Reproducibility of Results, Surveys and Questionnaires, Asthma, Mobile Applications
- Abstract
Background: Asthma impacts children's physical, emotional, and psychosocial Health-Related Quality of Life (HRQL). The EQ-5D-Y is a generic econometric instrument developed to measure HRQL in children., Objective: Evaluation of feasibility, validity, reliability, and responsiveness of EQ-5D-Y descriptive system and utility index to allow the assessment of HRQL in children with asthma, aged 8-11 years (self-response version) or under 8 years old (proxy-response version)., Methods: We used data from baseline to 10 months of follow-up of an observational, prospective study of children with persistent asthma recruited by pediatricians in Spain (2018-2020). HRQL instruments were administered through a smartphone application: ARCA app. The EQ-5D-Y is composed of a 5-dimension descriptive system, a utility index ranging from 1 to - 0.5392, and a general health visual analogue scale (EQ-VAS). The Pediatric Asthma Impact Scale (PROMIS-PAIS) includes 8 items, providing a raw score. Construct validity hypotheses were stated a priori, and evaluated following two approaches, multitrait-multimethod matrix and known groups' comparisons. Reliability and responsiveness subsamples were defined by stability or change in EQ-VAS and the Asthma Control Questionnaire (ACQ), to estimate the intraclass correlation coefficient (ICC) and the magnitude of change over time., Results: The EQ-5D-Y was completed at baseline for 119 children (81 self-responded and 38 through proxy response), with a mean age of 9.1 (1.7) years. Mean (SD) of the EQ-5D-Y utility index was 0.93 (0.11), with ceiling and floor effects of 60.3% and 0%, respectively. Multitrait-multimethod matrix confirmed the associations previously hypothesized for the EQ-5D-Y utility index [moderate with PROMIS-PAIS (0.38) and weak with ACQ (0.28)], and for the EQ-5D-Y dimension "problems doing usual activities" [moderate with the ACQ item (0.35) and weak with the PROMIS-PAIS item (0.17)]. Statistically significant differences were found in the EQ-5D-Y between groups defined by asthma control, reliever inhalers use, and second-hand smoke exposure, with mostly moderate effect sizes (0.45-0.75). The ICC of the EQ-5D-Y utility index in the stable subsamples was high (0.81 and 0.79); and responsiveness subsamples presented a moderate to large magnitude of change (0.68 and 0.78), though without statistical significance., Conclusions: These results support the use of the EQ-5D-Y as a feasible, valid, and reliable instrument for evaluating HRQL in children with persistent asthma. Further studies are needed on the responsiveness of the EQ-5D-Y in this population., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
19. Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma.
- Author
-
Valdesoiro-Navarrete L, León ME, Rodríguez M, Indiveri M, Ayats R, Larramona H, González MG, de la Cruz ÒA, and García MB
- Subjects
- Allergens therapeutic use, Child, Desensitization, Immunologic adverse effects, Humans, Omalizumab therapeutic use, Retrospective Studies, Treatment Outcome, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy
- Abstract
Background: In most cases, severe asthma in children has an allergic etiology, but allergen-specific immunotherapy (AIT) is contraindicated., Objective: This study aimed at analyzing the safety and efficacy of AIT in patients with severe asthma treated with omalizumab (OM)., Methods: A descriptive real-life study was carried out by reviewing medical records. Effectiveness was measured by the degree of control (CAN questionnaire), number of hospitalizations per year, number of exacerbations per year, and maintenance treatment and lung function (FEV1). Some adverse reactions occurred (AAI-EAACI-WAO guidelines)., Results: The retrospective study included 29 patients up to 18 years of age with severe asthma with OM plus AIT treatment. AIT treatment was started in a cluster schedule when patients treated with OM achieved disease control. Before starting AIT, patients were treated with OM for 1 year for achieving asthmatic control. AIT to mites (51%), Alternaria (37.9%), or pollens (10.3%) was administered. After one year with OM plus AIT,statistically significant differences in CAN scores and FEV1 measures were observed (P < 0.001). No patients under treatment with OM plus AIT required hospital admission. During the clustering schedule, only 3/64 doses showed systemic adverse reactions. During the AIT maintenance treatment, 348 doses were administered, with no significant adverse reactions., Conclusion: In this population-based study in children with severe asthma, the combined treatment with OM plus AIT was safe and effective. This strategy allows these pediatric patients to be safely treated with AIT.
- Published
- 2022
- Full Text
- View/download PDF
20. Successful removal of distal persistent foreign body airway with CO2 cryotherapy in a child.
- Author
-
Ayats-Vidal R, Vásquez-Pérez A, Gallego-Díaz M, Rosell A, Valdesoiro-Navarrete L, and Tazi-Mezalek R
- Abstract
We report a case of a nine-year-old boy with clinical evidence of foreign body (FB) aspiration with 3 months of delay in diagnosis. The bronchoscopy found soft tissue FB with surrounding inflamed granulation tissue at the entrance to the lateral segmental bronchus. Repeated attempts to remove the FB with flexible forceps were unsuccessful due to friable FB and granulation tissue. Ablation of the granulation tissue using nitrous oxide cryotherapy was then successfully performed and the distal and organic FB was extracted. Early diagnosis is important for minimizing granulation tissue development which complicates FB removal. Cryotherapy with a flexible bronchoscope is an option if organic FB cannot be removed using conventional bronchoscopic instrumentation., Competing Interests: ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
21. Pediatric asthma: The REGAP consensus.
- Author
-
Moral L, Asensi Monzó M, Juliá Benito JC, Ortega Casanueva C, Paniagua Calzón NM, Pérez García MI, Rodríguez Fernández-Oliva CR, Sanz Ortega J, Valdesoiro Navarrete L, and Valverde-Molina J
- Subjects
- Administration, Inhalation, Child, Consensus, Drug Therapy, Combination, Humans, Practice Guidelines as Topic, Quality of Life, Spain, Adrenergic beta-Agonists therapeutic use, Asthma diagnosis
- Abstract
Asthma is one of the main chronic diseases in childhood, due to its high prevalence and its social and health costs. This document is a summary of a consensus guideline approved by 6 Spanish pediatric societies related to asthma and endorsed by the Spanish Pediatric Association. Asthma is easily identifiable by clinical criteria in most patients. Spirometry and other tests are helpful for diagnosis, especially in atypical cases. Asthma exacerbation is a frequent manifestation of the disease and must be identified and treated promptly. When asthma symptoms are frequent and the quality of life is affected, maintenance treatment must be instituted to achieve control of the disease. Low-dose inhaled corticosteroids are effective and safe for long-term use. Education of the patient with asthma is essential for good control. The main reason for poor asthma control is non-compliance with treatment, either due to its erratic and insufficient administration, or due to poor application technique of inhaled drugs. If control is not obtained despite adequate treatment, the diagnosis must be reconsidered, as well as the factors or comorbidities that make control difficult. Other drugs can be added to avoid high doses of inhaled corticosteroids, notably montelukast or long-acting β2 adrenergic agonists. Severe or difficult-to-control asthma, which does not respond to the usual treatments, should be managed in specialized units., (Copyright © 2021 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
22. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
- Author
-
Nieto García A, Garriga-Baraut T, Plaza Martín AM, Nieto Cid M, Torres Borrego J, Folqué Giménez MDM, Lozano Blasco J, Bosque García M, Moreno-Galarraga L, Tortajada-Girbés M, Rivas Juesas C, Penín Antón M, Caballero-Rabasco MA, Gaboli M, López Neyra A, Navarro Morón J, Freixa Benavente A, Valdesoiro Navarrete L, Ballester Asensio E, Sanz Santiago V, Romero García R, Gimeno Díaz de Atauri Á, Valenzuela Soria A, Sánchez Mateos M, Batlles Garrido J, Andrés Martín A, Campos Alonso E, Aragón Fernández C, Vázquez Rodríguez E, Martínez Pardo L, Del-Río Camacho G, and Mazón Ramos Á
- Subjects
- Anti-Asthmatic Agents adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Child, Humans, Omalizumab adverse effects, Retrospective Studies, Treatment Outcome, Anti-Asthmatic Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Asthma drug therapy, Omalizumab therapeutic use
- Abstract
Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date., Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of the annual number of moderate-to-severe exacerbations compared with the baseline period., Results: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution., Conclusion: In this large, long-term, observational study, moderate-to-severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long-term treatment in pediatric patients with severe persistent allergic asthma., (© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
23. A Case of Persistent Air Leak Managed by Selective Left Main Bronchus Intubation in an Infant with Pulmonary Tuberculosis.
- Author
-
Vargas-Pons L, Valdesoiro Navarrete L, Sánchez Pérez S, Guijarro Casas E, Brun Lozano N, Renter Valdovinos L, and Corripio Collado R
- Subjects
- Chest Tubes, Humans, Infant, Infant Health, Male, Pneumonia complications, Pulmonary Emphysema complications, Bronchi, Intubation, Pneumothorax therapy, Tuberculosis, Pulmonary therapy
- Abstract
BACKGROUND Persistent air leak, or persistent pneumothorax, is defined as a pneumothorax that persists beyond the first week, or air leak through a chest drain for more than 48 hours. The most common findings in pediatric pulmonary tuberculosis are parenchymal disease and mediastinal lymphadenopathy, but airway obstruction can cause emphysema and pneumothorax. A case is presented of persistent air leak in a 3-month-old infant with pulmonary tuberculosis that was managed by selective left main bronchus intubation. CASE REPORT A 3-month-old boy presented with respiratory distress and fever. Imaging findings suggested pulmonary tuberculosis, and first-line anti-tuberculous treatment was initiated with isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). He was discharged home after eight days, but was admitted four days later with respiratory distress. Chest X-rays showed a tension pneumothorax that required drainage and chest computed tomography (CT) showed right lung emphysema. Bronchoscopy found extrinsic obstruction of both main bronchi. Chest drains continued to leak air leak after 48 h. Right middle and lower lobectomy and drainage of multiple lymph nodes resulted in significant improvement. He developed pneumonia and acute respiratory distress syndrome, which prevented mechanical ventilation. The left main bronchus was selectively intubated to allow the air leak to heal and to ventilate the lung. He was extubated 10 days later and recovered completely. CONCLUSIONS This case highlights that when medical management of persistent air leak associated with tuberculosis is not effective, surgery, active ventilation, and selective main bronchus intubation should be considered.
- Published
- 2020
- Full Text
- View/download PDF
24. [Kingella kingae: occult bacteriemia in a child].
- Author
-
Pineda Solas V, Valdesoiro Navarrete L, Fontanals Aymerich D, Llimiñana Ordas C, Antón López J, and Cabezas Maspoch MR
- Subjects
- Humans, Infant, Bacteremia diagnosis, Kingella kingae isolation & purification, Neisseriaceae Infections diagnosis
- Published
- 2002
25. [Splenic abscess and cat-scratch disease].
- Author
-
Valdesoiro Navarrete L, Pineda Solas V, Martín Martín C, Sanfeliu Sala I, Cabezas Maspoch RM, and Sánchez Oespina M
- Subjects
- Adolescent, Female, Humans, Abscess microbiology, Bartonella henselae, Cat-Scratch Disease complications, Splenic Diseases microbiology
- Abstract
Cat-scratch disease is caused by a Gram-negative bacillus known as Bartonella henselae. This disease is usually benign and causes regional adenitis that does not require treatment. However, some patients develop more serious atypical forms of the disease including prolonged systemic illness with hepatic and splenic abscesses.A 14-year-old girl was admitted to hospital with a 12-day history of persistent high fever and abdominal pain. Ultrasonography and computerized tomography of the abdomen revealed splenic abscesses. These findings, together with an antecedent of cat exposure, led to the suspicion of cat-scratch disease, which was confirmed by serology. The girl was treated with intramuscular ceftriaxone and clinical evolution was favorable. Splenic cat-scratch disease is infrequent. Cat-scratch disease sometimes presents as fever of unknown origin and consequently this disease should be considered in the differential diagnosis of prolonged fever. Although evolution is usually favorable, antibiotic therapy is recommended in systemic manifestations of cat-scratch disease.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.